Rational Use of Herbal Products in Pediatric Patients Treated With Anticancer Drugs in the European Union
Abstract
Introduction: The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated. Objectives were to evaluate the benefit–risk balance of commonly used herbal medicines in pediatric oncology and provide evidence‐based recommendations. Methods: A retrospective review of herbal medicine‐related inquiries submitted to the Angers Regional Pharmacovigilance Centre (2016–2019) was conducted. Fourteen medicinal plants were selected on the basis of their use for abdominal pain, appetite loss, nausea/vomiting, sleep, and anxiety. Their suitability for pediatric use, efficacy, toxicity, pharmacological mechanisms, and potential interactions with anticancer and supportive therapies were evaluated. Data were sourced from European Medicines Agency (EMA) monographs, PubMed, Memorial Sloan‐Kettering Cancer Center (MSKCC), and pharmacological reference texts. Benefit–risk ratios and recommendation levels were assigned, and recommendations of proper use were summarized for herbal medicines without any objections. Results: Six medicinal plants were deemed to have a favorable benefit–risk profile: leaf of peppermint, lemon balm and sweet fennel for abdominal pain; ginger for nausea and vomiting; lime tree and valerian for anxiety and sleep disorders. However, evidence remains limited, and product quality may vary. Sweet fennel and valerian should be used with caution in the presence of cytochrome P450 3A4 substrate. Conclusion: Some medicinal plants may be cautiously considered in pediatric oncology, but the risks of pharmacokinetic and pharmacodynamic interactions are substantial. This study proposes a shortlist of plants that may be considered and HMPs with potentially good benefit–risk ratios. These findings should not be interpreted as therapeutic recommendations.
Related
- Abstracts from the 3rd International BeSafeBeeHoney Conference - BeeForward: building a safe European value chain in beekeeping products.
- Association between nirsevimab coverage and pediatric emergency department visits for bronchiolitis in 12 European countries: An interrupted time-series analysis
- Use of landiolol in septic shock patients with new onset of atrial fibrillation: a European Delphi consensus
- Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)
- Safety and effectiveness of caplacizumab in pediatric patients with iTTP: real-world experience
BibTeX
@article{mahot2026rational,
title = {{Rational Use of Herbal Products in Pediatric Patients Treated With Anticancer Drugs in the European Union}},
author = {Orianne Mahot and Mathieu Corvaisier and Laurence Spiesser‐robelet and Mylène Duplan and Isabelle Pellier and Delphine Bourneau-Martin and Séverine Derbré},
journal = {Pediatric Blood and Cancer},
year = {2026},
month = sep,
doi = {10.1002/1545-5017.70459},
url = {https://hal.science/hal-05745768v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Rational Use of Herbal Products in Pediatric Patients Treated With Anticancer Drugs in the European Union
AU - Orianne Mahot
AU - Mathieu Corvaisier
AU - Laurence Spiesser‐robelet
AU - Mylène Duplan
AU - Isabelle Pellier
AU - Delphine Bourneau-Martin
AU - Séverine Derbré
PY - 2026
DA - 2026/09/10
JO - Pediatric Blood and Cancer
DO - 10.1002/1545-5017.70459
UR - https://hal.science/hal-05745768v1
AB - Introduction: The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated. Objectives were to evaluate the benefit–risk balance of commonly used herbal medicines in pediatric oncology and provide evidence‐based recommendations. Methods: A retrospective review of herbal medicine‐related inquiries submitted to the Angers Regional Pharmacovigilance Centre (2016–2019) was conducted. Fourteen medicinal plants were selected on the basis of their use for abdominal pain, appetite loss, nausea/vomiting, sleep, and anxiety. Their suitability for pediatric use, efficacy, toxicity, pharmacological mechanisms, and potential interactions with anticancer and supportive therapies were evaluated. Data were sourced from European Medicines Agency (EMA) monographs, PubMed, Memorial Sloan‐Kettering Cancer Center (MSKCC), and pharmacological reference texts. Benefit–risk ratios and recommendation levels were assigned, and recommendations of proper use were summarized for herbal medicines without any objections. Results: Six medicinal plants were deemed to have a favorable benefit–risk profile: leaf of peppermint, lemon balm and sweet fennel for abdominal pain; ginger for nausea and vomiting; lime tree and valerian for anxiety and sleep disorders. However, evidence remains limited, and product quality may vary. Sweet fennel and valerian should be used with caution in the presence of cytochrome P450 3A4 substrate. Conclusion: Some medicinal plants may be cautiously considered in pediatric oncology, but the risks of pharmacokinetic and pharmacodynamic interactions are substantial. This study proposes a shortlist of plants that may be considered and HMPs with potentially good benefit–risk ratios. These findings should not be interpreted as therapeutic recommendations.
SN - 1545-5009
SN - 1545-5017
ER -